Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I received this in an email today:
PRODUCT RELEASE ANNOUNCEMENT
PrintRite3D® INSPECT™ 2.0 OEM Developers Kit
INSPECT 2.0 Point Cloud
Sigma Labs latest software release is now available as a web based application designed for seamlessly integrating INSPECT™ data analytics with all metal OEM machine solutions. For OEMs who have already taken the first step in process monitoring, Sigma Labs web APIs provide the platform and architecture for displaying results and creating quality metrics making the monitoring data actionable. While Sigma Labs provides the backbone for process interrogation and visualization, OEMs have the flexibility to customize the overall user experience and interface.
Sigma Labs web APIs allow end users to access real-time build data locally or remotely.
All PrintRite3D® OEM partners can provide end users with access to powerful data reduction tools and baseline comparison technology.
3D Visualization
This latest INSPECT 2.0 software release includes new features forprocess improvement and part validation.
XY Position Mapping
Location mapping for Part-by-Part discrimination of off nominal process conditions with 2D and 3D imaging provide for production process optimization and anomaly detection.
Contact us for further details:
Sales@sigmalabsinc.com
Ron.Fisher@sigmalabsinc.com
+1 (330) 842-4864
+1 (505) 438-2576
www.sigmalabsinc.com
FWIW: The CEOs interviewed on the Stock Day Podcast did not incur any charges for their time with Uptick Newswire CEO Everett Jolly. Contact us at (602) 441-3474 if you would like further information.
They're probably all or nothing asks.
I am surprised as I thought the interview was positive.
20M on the ask at .0011. Not a positive response. IMO
I thought he said 10-30 days, but it was hard to hear this one part.
I was able to play another interview on Uptick Newswire without going through AudioBoom, so don't understand it either yet.
Interview is out: Featured Interview: CEO Steve Berman of ON4 Communications, Inc. (OTCPink: ONCI): ON4… goo.gl/fb/wMFhq6
Tweet from Uptick Newswire just now: Lot's of questions regarding $ONCI 's interview. Keep an eye on our feed for when it goes live.
Thanks! I was curious too, but working the patience.
New tweet: $TTCM manipulators you have been put on notice.. I believe in #KlickZie! Consider this my "form 4"..
Not for me. I'm working right now & don't have L2. It sure looks like a signal. What that signal is? I don't know.
There were 3 trades for 911 shares today.
They put the zeroes on the wrong side. That's an expensive mistake! LOL
To me, dealing with multiple melt pools shouldn't be a tough enhancement - given the benefits associated with object-oriented coding. Of course, there will need to be a lot of verification & validation of the new feature.
Another new tweet: Next Asian Auto Manufacturer announcement to come tomorrow or early next week
#newerabeginning
New tweet: On4 Communications CEO Steve Bermen to be inteviewed by Uptick Newswire Magazine next week Date to be annoncued ASAP
Thanks for letting S Gordon know about the wrong exchange on the presser. I suspect there to be little to know sales from this contract, while the verify the software on different new printer.
Does anyone have any idea on what the Solar Turbines contract sales amount is?
ONCI tweeted: 1st of 3 significant announcements coming from Asia next week
#AcceleratedGrowthStarting
Organovo Announces CEO Transition
Apr. 11, 2017 4:05 PM
Taylor J. Crouch Named Chief Executive Officer, Effective April 24, 2017
Keith Murphy to Step Down as Chief Executive Officer, Remains on Board of Directors
SAN DIEGO, April 11, 2017 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (ONVO) (“Organovo”), a three-dimensional biology company focused on delivering scientific and medical breakthroughs using its 3D bioprinting technology, today announced that Keith Murphy will be stepping down as chief executive officer to pursue entrepreneurial opportunities, effective April 21, 2017. Organovo’s board of directors has appointed Taylor J. Crouch, previously CEO of eStudySite, a leading investigative clinical research company, to succeed Mr. Murphy as CEO. Mr. Murphy will remain chairman of the board, and will serve as an advisor to the Company to ensure a seamless transition and offer his counsel and expertise.
Lead director, Kirk Malloy, Ph.D. stated, “On behalf of the board, I want to thank Keith for his many contributions to Organovo and the groundbreaking innovations he helped pioneer. Keith saw the value in 3D bioprinting technology before the market existed, and had the vision to take it from its earliest stages in academic labs, and develop it into a global business with a robust commercial platform and strong IP portfolio. We support Keith’s decision to step down and agree this is the opportune time to bring Taylor on to lead Organovo in its next phase of commercial growth. We also appreciate his willingness to continue to serve the Company.”
Mr. Murphy said, “I am extremely proud of the progress we have made in the last ten years achieving our vision for Organovo. Our 3D bioprinted human tissues are a disruptive and game-changing technology. Founding Organovo and guiding us to our leadership position in 3D bioprinting has been a privilege, and I am extremely grateful to my Organovo colleagues who assisted in building this success, as well as all of our partners and customers. I am a true believer in our existing tissue research services, the potential of our therapeutic liver tissue, and the future opportunities enabled by our platform technology. The time is right to bring in a CEO with the relevant commercial experience to lead the company into its next stage. I have great confidence in Organovo’s continued growth and success, and I look forward to working with the board and Taylor over the coming months to ensure that this transition is seamless for all of our stakeholders.”
Mr. Crouch said, “I am excited and honored to succeed Keith as Organovo’s CEO. Keith is an exceptional leader who built Organovo into the strong global company it is today. I look forward to working with the seasoned management team and all my talented new colleagues to further advance 3D human tissue bioprinting technology, advance solutions that benefit patients and drive the commercialization and scale of our business.”
Commenting on Mr. Crouch’s appointment, Dr. Malloy said, “Taylor is uniquely positioned to lead our growing company into its next phase given his significant commercial and operations experience. We are confident that Taylor’s extensive skills and expertise in the biotechnology and life sciences industries align with Organovo’s strategy to capitalize fully on its growth opportunities. The board looks forward to working with Taylor and the management team to execute against our strategy and continuing to create meaningful value for stockholders.”
About Taylor J. Crouch
Mr. Crouch has over 25 years of experience building and leading technology, expertise and product-based companies in the life sciences and biotech industries. For more than seven years, he has managed and served as an operational investor in a group of leading clinical research site companies. Specifically, Mr. Crouch served as Chief Executive Officer at eStudySite, a position he held from January 2009 to June 2016; as Executive Chairman of Meridien Research from December 2013 to September 2016; and as a Director of the National Research Institute from September 2011 through July 2016. He was instrumental in building these three sister companies, and helping them to achieve significant and profitable growth and to become recognized leaders in their respective fields of infectious disease, CNS disorders and metabolic disease. Prior to this, Mr. Crouch served as Senior Vice President of Operations/President International at Ligand Pharmaceuticals from 2005 to 2007, with responsibilities for new business development, technical operations, international sales and clinical research. Prior to Ligand, he was President and Chief Operating Officer of Discovery Partners International (DPII) (NASDAQ: formerly DPII – a large drug discovery services and technology provider). Earlier in his career, he was Chief Executive Officer of Variagenics (NASDAQ: formerly VGNX – a leading pharmacogenomics company), Senior Vice President of Marketing and Sales at Parexel – a global CRO, and he also held international management positions in new product development and commercialization at Pfizer and Schering Plough. Mr. Crouch holds a BSE in chemical engineering, cum laude, from Princeton University and an MBA in international marketing and finance from the University of Chicago.
About Organovo Holdings, Inc.
Organovo designs and creates functional, three-dimensional human tissues for use in medical research and therapeutic applications. The Company develops 3D human tissue models through internal development and in collaboration with pharmaceutical, academic and other partners. Organovo's 3D human tissues have the potential to accelerate the drug discovery process, enabling treatments to be developed faster and at lower cost. The Company’s ExVive Human Liver and Kidney Tissues are used in toxicology and other preclinical drug testing. The Company also actively conducts early research on specific tissues for therapeutic use in direct surgical applications. In addition to numerous scientific publications, the Company’s technology has been featured in The Wall Street Journal, Time Magazine, The Economist, Forbes, and numerous other media outlets. Organovo is changing the shape of life science research and transforming medical care. Learn more at www.organovo.com.
Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause the Company's actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products and services based on its technology; the expected benefits and efficacy of the Company's products, services and technology; the Company’s ability to successfully complete studies and provide the technical information required to support market acceptance of its products, services and technology, on a timely basis or at all; the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies, including its use of third party distributors; the Company's ability to successfully complete the contracts and recognize the revenue represented by the contracts included in its previously reported total contract bookings and secure additional contracted collaborative relationships; the final results of the Company's preclinical studies may be different from the Company's studies or interim preclinical data results and may not support further clinical development of its therapeutic tissues; the Company may not successfully complete the required preclinical and clinical trials required to obtain regulatory approval for its therapeutic tissues on a timely basis or at all; and the Company’s ability to meet its fiscal year 2017 outlook and/or its long-range outlook. These and other factors are identified and described in more detail in the Company's filings with the SEC, including its Annual Report on Form 10-K filed with the SEC on June 9, 2016 and its Quarterly Report on Form 10-Q filed with the SEC on February 9, 2017. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that the Company may issue in the future. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events or circumstances or to reflect the occurrence of unanticipated events.
Investor Contact:
Steve Kunszabo
Organovo Holdings, Inc.
+1 (858) 224-1092
skunszabo@organovo.com
Press Contact:
Jessica Yingling, Ph.D.
Little Dog Communications
+1 (858) 480-2411
jessica@litldog.com
Yes, I am a long term shareholder that believes in what this company is trying to do. I do have some understanding of the technology.
SGLB is down 8%. Ouch!
Ouch!
I thought his answer to the America Makes question was very positive. Basically, it is finishing up & the (preliminary) final presentation was already presented. He felt that Sigma Labs had proven their IPQA technology - which was one of the expected conclusions. Here's a link to the presentation that was probably posted here before: https://www.americamakes.us/news-events/press-releases/item/950-america-makes-and-ansi-release-preliminary-final-draft-of-additive-manufacturing
Here's a link to a webpage which discusses the AF Booster program: http://www.losangeles.af.mil/News/Article-Display/Article/734627/af-releases-final-booster-propulsion-technology-maturation-baa-award
AF Releases Final Booster Propulsion Technology Maturation BAA Award
By Public Affairs Office, Space and Missile Systems Center / Published January 27, 2016
A United Launch Alliance Atlas V space launch vehicle, which uses the Russian made RD-180 propulsion system awaits to be stacked at Space Launch Complex 41 at Cape Canaveral Air Force Station, Fla. A total of 10 awards have been made under the Booster Propulsion Technology Maturation Broad Agency Announcement (BAA) solicitation supporting technology maturation and risk reduction for rocket propulsion system development. The BAA awards are part of a comprehensive Air Force plan to transition off the Russian made RD-180 propulsion system used on the Atlas V rocket by investing in industry launch solutions . (U.S. Air Force Photo)
LOS ANGELES AIR FORCE BASE, Calif. -- The Space and Missile Systems Center released the tenth and final award notice on Jan. 27 under the Booster Propulsion Technology Maturation Broad Agency Announcement (BAA) solicitation supporting technology maturation and risk reduction for rocket propulsion system development. The Air Force's portfolio of investments through this BAA is in the focus areas of Material Manufacturing and Development, primarily focused on reducing the cost of future engines, and Advanced Technologies, primarily focused on advancing the state of the art for future engines. These acquisitions will mature booster propulsion technology and reduce risk for the U.S. domestic industry base.
Ten awards totaling approximately $34.6 million have been awarded under this BAA since Nov. 4, 2015.
The first award under this BAA was to Johns Hopkins University for Evaluation of "Additively Manufactured Liquid Rocket Engine Cooling Channels" for approximately $545,000 to improve performance in next-generation rocket engine thrust chambers and cooling channels.
The second award was to Tanner Research Inc. for "Solid Rocket Motor (SRM) Ignition System with Built-In Test (BiT)" for approximately $902,000 to develop an ignition system that can simplify detection of defective solid rocket motors.
The third award was to Johns Hopkins University for "Performance Sensitivity of Rocket Engine Cooling Channels" for approximately $935,000 to address industry knowledge gaps in propellant characteristics to enable LNG/Methane booster engine development.
The fourth award was to Moog Inc for "Non-Destructive Evaluation, Standards, and Testing" for approximately $728,000 to develop additive manufacturing technology for propellant control valves for use in a wide range of liquid engine systems.
The fifth award was to Orbital ATK for "Segmented Composite Case Advanced Technology" for approximately $3.13 million to focus on reducing weight of solid rocket motor case joints and improving reliability.
The sixth award was to Aerojet-Rocketdyne for "Additive Manufacturing Qualification Process for Reduced Booster Propulsion Life Cycle Cost" for approximately $6 million to develop a qualification process for additively manufactured engine parts that does not currently exist.
The seventh award was to Northrop Grumman for "Turbopump Assembly Additive Manufacturing" for approximately $5.47 million to improve technological readiness of an additively manufactured LOX/Methane booster engine TPA for insertion into a rocket propulsion system.
On Jan. 25, SMC released the eight and ninth awards The eighth award was to Boeing for "Additively Manufactured High Pressure Engine Dome" for approximately $6.19 million to develop a full scale, complex, thick-walled engine component that advances additive manufacturing state of the art, and is targeted for integration into an engine development.
The ninth award was to Arctic Slope Technical Services for "A Low Cost, High Performance Preburner for Oxygen Rich Staged Combustion (ORSC)" for approximately $3.69 million to develop a preburner that implements a "continuous dilution" approach to minimize preburner exit thermal gradients to enhance system reliability and reduce life cycle cost.
On Jan. 27, SMC released the tenth and final award was to Northrop Grumman for "Duct-cooled, Carbon Silicon Carbide (C/SiC) Thrust Chamber Technology" for approximately $7.03 million to demonstrate both new manufacturing technology and a new nozzle cooling approach that will lead to a lighter combustion chamber design that is less expensive to produce. The targeted completion date of this effort is Jan. 26, 2018.
The BAA awards are part of a comprehensive Air Force plan to transition off the Russian made RD-180 propulsion system used on the Atlas V rocket by investing in industry launch solutions with the ultimate goal to competitively procure launch services in a robust domestic launch market.
"Many programs focus on risk reduction efforts too late to make a difference. By leading off this program with these awards, we have given industry tools to help ready themselves for developing launch systems, including the associated propulsion systems, that we will rely on to launch the nation's satellites in the future," said Lt. Gen. Samuel Greaves, the Air Force's Program Executive Officer for Space and SMC commander. "This is essential in order to solidify U.S. assured access to space, transition the EELV program away from strategic foreign reliance, and support the U.S. launch industry's commercial viability in the global market."
Air Force Space Command's Space and Missile Systems Center, located at Los Angeles Air Force Base, Calif., is the U.S. Air Force's center of acquisition excellence for acquiring and developing military space systems. Its portfolio includes the Global Positioning System, military satellite communications, defense meteorological satellites, space launch and range systems, satellite control networks, space based infrared systems and space situational awareness capabilities.
Media representatives can submit questions for response regarding this topic by sending an e-mail to smcpa.media@us.af.mil
I need to look into the AF Booster program.
Sigma Labs reports Q4 results:
• Sigma Labs (NASDAQ:SGLB): Q4 EPS of -$0.04
• Revenue of $324.19M (-44.7% Y/Y)
Here's the text:
Sigma Labs Announces Full Year 2016 Financial Results
Mar. 30, 2017 8:00 AM
GlobeNewswire
SANTA FE, N.M., March 30, 2017 (GLOBE NEWSWIRE) -- Sigma Labs, Inc. (SGLB) (“Sigma Labs” or the “Company”), a provider of quality assurance software under the PrintRite3D® brand, today announced financial results for the three and twelve months ended December 31, 2016.
Recent Highlights
Completed a public offering that raised gross proceeds of approximately $5.8 million concurrent with uplisting to the NASDAQ Capital Market following a reverse stock split. The offering provided funds for the Company’s 2017 growth plans, while moving to the NASDAQ allows for a broader base of potential institutional investors.
The Company also formed strategic alliances with Morf3D and Jaguar Precision Machine (“Jaguar”) to serve the additive manufacturing (“AM”) needs of the aerospace and defense (“A&D”) sector. As part of these agreements, the Company’s PrintRite3D® software will be licensed to Morf3D and Jaguar, and Sigma Labs will utilize its on-site EOS machine to form aerospace components under contract using additive manufacturing. The strategic alliances are expected to significantly enhance the Company’s 2017 top line growth profile.
Sigma Labs announced additional contract wins with Aerojet Rocketdyne, Pratt & Whitney, Honeywell, and Siemens during the fourth quarter and early part of 2017.
The Company also announced, subsequent to the end of 2016, that a leading European AM equipment provider had signed onto its OEM Partner Program as part of a long-term commercial agreement, expanding an existing relationship. Sigma Labs’ PrintRite3D® applications will be embedded in certain of the OEM’s AM machines prior to them being sold.
“We’re already well into 2017 and, with so much behind us, I feel the Company is in a position to see greatly improved performance going forward,” said Mark Cola, President & CEO of Sigma Labs. “In a relatively short period of time we’ve raised much-needed growth capital, uplisted to the NASDAQ, signed several important strategic relationships, and won contracts with marquee customers such as Pratt & Whitney and Siemens. We’ve also landed a significant OEM Partner and are actively working on other business development initiatives, setting the stage for stronger growth in the quarters to come. In effect, we’ve done what we said we would do – winning new customers, joining with other leading companies to move the industry forward, and improving our balance sheet to take advantage of the opportunities to come. This year we have the wind at our backs, with unlimited potential for taking additive manufacturing to a whole new level.”
2016 Full Year Financial Results
Revenue for the year ended December 31, 2016 was approximately $1.0 million versus approximately $1.2 million for 2015. The Company reported a net loss for the year of approximately $2.2 million, or $(0.35) per diluted share, versus a loss of approximately $1.7 million, or $(0.27) per diluted share, for 2015.
Investor Conference Call
The Company will host a conference call to discuss its 2016 full year financial results today, March 30, 2017, at 11:00 a.m. Eastern Time. To participate in the call, please dial toll free 1-844-802-2441, or 1-412-317-5134, approximately five minutes before the conference call time stated above. A live webcast of the call can also be accessed on the Sigma Labs website at www.sigmalabsinc.com. A recording will be available on the Company's website upon completion of the call.
About Sigma Labs, Inc.
Sigma Labs, Inc. is a provider of quality assurance software under the PrintRite3D® brand and a developer of advanced, in-process, non-destructive quality assurance software for commercial firms worldwide seeking productive solutions for advanced manufacturing. For more information please visit us at www.sigmalabsinc.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements often contain words such as "expects," "anticipates," "intends," "believes" or "will." Our forward-looking statements are subject to a number of risks, uncertainties and assumptions that could adversely affect us, including the risks set forth in our annual report on Form 10-K. The forward-looking statements in this press release are made only as of the date of this press release. We undertake no obligation to update our forward-looking statements, whether as a result of new information, future events or otherwise.
Sigma Labs, Inc.
Condensed Statements of Operations
Three Months Ended Twelve Months Ended
Years Ended December 31 Years Ended December 31
2016 2015 2016 2015
REVENUE $ 324,192 $ 586,295 $ 966,422 $ 1,234,810
COST OF REVENUE 21,158 75,625 228,902 214,004
GROSS PROFIT 303,034 510,670 737,520 1,020,806
EXPENSES:
Other General and Administration 444,520 395,987 1,790,096 1,282,952
Payroll Expense 299,346 247,173 1,026,840 585,706
Stock-Based Compensation 105,004 39,938 341,558 518,438
Research and Development 4,488 124,009 92,992 330,554
Total Expenses 853,358 807,107 3,251,486 2,717,650
OTHER INCOME (EXPENSE)
Interest Income 67 203 355 1,340
Other Income 20,077 - 51,703 -
Other Income-Decrease in fair value of derivative liabilities 354,644 - 354,644 -
Other Expense - Debt discount amortization (89,570 ) - (89,570 )
Loss on Investment in Joint Venture 105 (670 ) - (778 )
Total Other Income 285,323 (467 ) 317,132 562
LOSS BEFORE PROVISION FOR INCOME TAXES (265,001 ) (296,904 ) (2,196,834 ) (1,696,282 )
Provision for income Taxes - - - -
Net Loss $ (265,001 ) $ (296,904 ) $ (2,196,834 ) $ (1,696,282 )
Net Loss per Common Share - Basic and Diluted $ (0.04 ) $ (0.05 ) $ (0.35 ) $ (0.27 )
Weighted Average Number of Shares
Outstanding - Basic and Diluted 6,267,577 6,237,511 6,249,609 6,228,108
Sigma Labs, Inc.
Condensed Balance Sheets
December 31, 2016 December 31, 2015
ASSETS
Current Assets:
Cash $ 398,391 $ 1,539,809
Accounts Receivable, net 288,236 280,222
Inventory 187,241 20,129
Prepaid Assets 36,056 38,687
Total Current Assets 909,924 1,878,847
Other Assets:
Property and Equipment, net 564,933 714,754
Intangible Assets, net 226,450 167,644
Investment in Joint Venture 500 9,222
Prepaid Stock Compensation 167,562 418,547
Total Other Assets 959,445 1,310,167
TOTAL ASSETS $ 1,869,369 $ 3,189,014
LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities:
Accounts Payable 112,175 38,393
Notes Payable, net of original issue discount $79,886 561,834 -
Accrued Expenses 125,116 71,523
Total Current Liabilities 799,125 109,916
Long-Term Liabilities
Derivative Liability 93,206 -
Total Long-Term Liablitiy 93,206 -
TOTAL LIABILITIES 892,331 109,916
Stockholders' Equity
Preferred Stock, $0.001 par; 10,000,000 shares authorized;
None issued and outstanding - -
Common Stock, $0.001 par; 15,000,000 shares authorized;
6,267,577 and 6,239,073 issued and outstanding at
December 31, 2016 and 2015, respectively 6,268 6,239
Additional Paid-In Capital 10,731,724 10,636,979
Accumulated Deficit (9,760,954 ) (7,564,120 )
Total Stockholders' Equity 977,038 3,079,098
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 1,869,369 $ 3,189,014
Investor Relations Contact:
Chris Witty
cwitty@darrowir.com; 646-438-9385
Source: Sigma Labs, Inc. 2017 GlobeNewswire, Inc.
0
The CEO needs to stop tweeting actions which he fails to follow through on. Where's the imminent PR? Imminent passed a couple weeks ago.
I have a Twitter account & follow @sigmalabsinc. It does not appear that any auto makers follow them. However, NASDAQ does. Also, you cannot discern when followers started to follow an account.
Giorgio should tweet about it too!
I'm hoping that this is a good place to load a little more & offset some of my losses. I don't like the 3.10 on the BID.
I wonder what the price would be without the 150M shares of dilution?
In retrospect, I think this is an automated update & doesn't mean anything... Will keep watching.
I'll keep watching the NV SOS for Nyxio Corp filing. Hopefully, the Revoked status gets updated soon.
It mean's there is activity with regard to reinstatement of Nyxio Corp. I have no idea how this will impact the NYXO stock, other than it is more solid evidence of progress than some Tweets.
There's an update to our feed for NV SOS: * These fees are current as of today's date of 03/09/2017 06:37 AM but can change based on events occurring on future dates. Calculated fees for entities in Default or Revoked status do not include fees and penalties due to resignation or other registered agent deficiency or being on administrative hold. For these types of inquiries please contact our office. The above fees assume that a State Business License Exemption does not apply. Exemptions from the State Business License may not be filed online.
Anything to make a buck on a market down day.